PL212132B1 - Zastosowanie treosulfanu - Google Patents

Zastosowanie treosulfanu

Info

Publication number
PL212132B1
PL212132B1 PL356240A PL35624000A PL212132B1 PL 212132 B1 PL212132 B1 PL 212132B1 PL 356240 A PL356240 A PL 356240A PL 35624000 A PL35624000 A PL 35624000A PL 212132 B1 PL212132 B1 PL 212132B1
Authority
PL
Poland
Prior art keywords
treosulfan
use according
bone marrow
patient
agent
Prior art date
Application number
PL356240A
Other languages
English (en)
Polish (pl)
Other versions
PL356240A1 (en
Inventor
Joachim Baumgart
Original Assignee
Medac Klinische Spezialpraep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medac Klinische Spezialpraep filed Critical Medac Klinische Spezialpraep
Publication of PL356240A1 publication Critical patent/PL356240A1/xx
Publication of PL212132B1 publication Critical patent/PL212132B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Materials For Medical Uses (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
PL356240A 1999-11-05 2000-11-03 Zastosowanie treosulfanu PL212132B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19953517A DE19953517C1 (de) 1999-11-05 1999-11-05 Verwendung von Treosulfan zur Konditionierung von Patienten vor Knochemarktransplantation oder Blutstammzelltransplantation
PCT/EP2000/010871 WO2001032154A2 (de) 1999-11-05 2000-11-03 Verwendung von treosulfan zur konditionierung von patienten vor knochenmarktransplantation oder blutstammzelltransplantation

Publications (2)

Publication Number Publication Date
PL356240A1 PL356240A1 (en) 2004-06-28
PL212132B1 true PL212132B1 (pl) 2012-08-31

Family

ID=7928187

Family Applications (1)

Application Number Title Priority Date Filing Date
PL356240A PL212132B1 (pl) 1999-11-05 2000-11-03 Zastosowanie treosulfanu

Country Status (16)

Country Link
US (1) US7199162B1 (cg-RX-API-DMAC7.html)
EP (1) EP1227808B1 (cg-RX-API-DMAC7.html)
JP (1) JP4846151B2 (cg-RX-API-DMAC7.html)
AT (1) ATE251455T1 (cg-RX-API-DMAC7.html)
AU (1) AU777527B2 (cg-RX-API-DMAC7.html)
BG (1) BG65845B1 (cg-RX-API-DMAC7.html)
CA (1) CA2389896C (cg-RX-API-DMAC7.html)
CZ (1) CZ299701B6 (cg-RX-API-DMAC7.html)
DE (2) DE19953517C1 (cg-RX-API-DMAC7.html)
EA (1) EA004543B1 (cg-RX-API-DMAC7.html)
ES (1) ES2208435T3 (cg-RX-API-DMAC7.html)
HU (2) HU227332B1 (cg-RX-API-DMAC7.html)
NO (2) NO329616B1 (cg-RX-API-DMAC7.html)
PL (1) PL212132B1 (cg-RX-API-DMAC7.html)
UA (1) UA73961C2 (cg-RX-API-DMAC7.html)
WO (1) WO2001032154A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
JP7431815B2 (ja) * 2018-09-26 2024-02-15 メダック ゲゼルシャフト フィア クリニッシェ スペツィアルプレパラーテ ミット ベシュレンクタ ハフトゥンク トレオスルファンの結晶形
PT4257122T (pt) 2018-09-26 2026-06-08 Medac Ges Fr Klinische Spezialprparate Mbh Liofilizado de treossulfano
EP3856252A1 (en) 2018-09-26 2021-08-04 medac Gesellschaft für klinische Spezialpräparate mbH Solution comprising treosulfan

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376546A (en) * 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
DE4421391C1 (de) * 1994-06-18 1995-11-30 Gsf Forschungszentrum Umwelt Verwendung von Antikörpern gegen T-Zellen zur verlängerten Immunsuppression
WO2000045842A2 (en) * 1999-02-04 2000-08-10 The General Hospital Corporation Methods for human allografting

Also Published As

Publication number Publication date
CA2389896A1 (en) 2001-05-10
ATE251455T1 (de) 2003-10-15
CZ20021562A3 (cs) 2002-10-16
BG65845B1 (bg) 2010-03-31
EP1227808B1 (de) 2003-10-08
NO2019032I1 (no) 2019-07-23
DE50004024D1 (de) 2003-11-13
EP1227808A2 (de) 2002-08-07
CZ299701B6 (cs) 2008-10-22
AU1391801A (en) 2001-05-14
WO2001032154A2 (de) 2001-05-10
DE19953517C1 (de) 2001-08-09
NO20022109L (no) 2002-07-01
US7199162B1 (en) 2007-04-03
NO329616B1 (no) 2010-11-22
ES2208435T3 (es) 2004-06-16
EA004543B1 (ru) 2004-06-24
AU777527B2 (en) 2004-10-21
HUP0203277A2 (en) 2003-01-28
PL356240A1 (en) 2004-06-28
BG106772A (bg) 2003-02-28
NO20022109D0 (no) 2002-05-02
CA2389896C (en) 2007-04-10
UA73961C2 (uk) 2005-10-17
WO2001032154A3 (de) 2002-01-24
JP2003513034A (ja) 2003-04-08
JP4846151B2 (ja) 2011-12-28
EA200200535A1 (ru) 2002-10-31
HU227332B1 (en) 2011-03-28
HUS1900041I1 (hu) 2019-10-28

Similar Documents

Publication Publication Date Title
US6586428B2 (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
CZ290120B6 (cs) Sdruľená kompozice paclitaxelu, docetaxelu nebo jejich analogu
KR100718946B1 (ko) 효과적인 항종양 치료
JP2007535525A (ja) β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用
EP0344880B1 (en) Pharmaceutical compositions with anti-cancer activity
ME00056B (me) Kombinacija kombrestatina i anti-kancer agensa
KR20130118981A (ko) 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물
JP4846151B2 (ja) 骨髄もしくは血液幹細胞の移植前の患者のコンディショニングのためのトレオスルファンの使用
KR20210039414A (ko) 암의 치료를 위한 병용 요법
EP1200099B1 (en) Synergistic composition comprising daunorubicin derivatives and antimetabolite compounds
Veys et al. Recombinant interferon gamma in rheumatoid arthritis. A double-blind study comparing Immuneron (recombinant interferon gamma) with placebo
KR20220082862A (ko) 혈액 악성 종양을 치료하기 위한 병용 요법
Tsavaris et al. Concomitant administration of 4-hydroxypyrazolopyrimidine (allopurinol) and high-dose continuous infusion 5-fluorouracil
Pratesi et al. Effects of Tauromustine, a Water-Soluble Nitrosourea Compound, on NMU-1 Murine Lung Tumor
Taguchi et al. Combination effect of human recombinant TNF (PT-050) and antitumor drugs
HK40040825A (zh) 用於治疗癌症的组合疗法
Marshall et al. Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons
WO2004073719A1 (en) A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent
HK1128234A1 (en) Combination comprising combretastatin and anticancer agents
HK1128234B (en) Combination comprising combretastatin and anticancer agents